Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis -> Clinical Therapy

High concordance rate on SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates

Rudolf Werner, Thorsten Derlin, Steven Rowe, Lena Bundschuh, Gabriel Sheikh, Martin Pomper, Andreas Buck, Frank Bengel, Ralph Bundschuh and Constantin Lapa
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 363;
Rudolf Werner
1Department of Nuclear Medicine Hannover Medical School Hannover Germany
2Department of Nuclear Medicine Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thorsten Derlin
1Department of Nuclear Medicine Hannover Medical School Hannover Germany
2Department of Nuclear Medicine Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Rowe
3Johns Hopkins Medical Institutions Baltimore MD United States
6Johns Hopkins Medical Institutions Baltimore MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lena Bundschuh
4Department of Nuclear Medicine University Medical Center Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Sheikh
5Department of Nuclear Medicine Augsburg University Hospital Augsburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Pomper
3Johns Hopkins Medical Institutions Baltimore MD United States
6Johns Hopkins Medical Institutions Baltimore MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Buck
7Department of Nuclear Medicine University Hospital Wuerzburg Wurzburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Bengel
1Department of Nuclear Medicine Hannover Medical School Hannover Germany
2Department of Nuclear Medicine Hannover Medical School Hannover Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Bundschuh
4Department of Nuclear Medicine University Medical Center Bonn Bonn Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constantin Lapa
5Department of Nuclear Medicine Augsburg University Hospital Augsburg Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

363

Objectives: Recently, a standardized framework system for interpreting somatostatin receptor (SSTR)-targeted PET/CTs, termed SSTR-Reporting and Data System (RADS) 1.0, has been introduced providing reliable standards and criteria for SSTR PET. We determined the interobserver reliability of SSTR-RADS for interpretation of 68Ga-DOTATOC PET/CT scans in a multicentric, randomized setting.

Methods: A set of 51 randomized 68Ga-DOTATOC PET/CT scans was independently assessed by four blinded readers with different levels of experience (2 experienced readers (ER) and 2 inexperienced readers (IR)) trained with SSTR-RADS 1.0 criteria (based on a 5-point scale (from 1 = definitively benign to 5 = high certainty that neuroendocrine tumor is present)). Per scan, SSTR-RADS scores were assigned to a maximum of 5 target lesions (TL). An overall scan impression based on SSTR-RADS was indicated, and interobserver agreement rates on a TL-based, on an organ-based, and on an overall SSTR-RADS score-based level were computed. Readers were also asked to indicate whether peptide receptor radionuclide therapy (PRRT) should be considered based on the assigned RADS scores.

Results: Among the selected TL, 153 were chosen by at least 2 individual observers (all 4 readers selected the same target lesion in 58 of 153 [37.9%] instances). The interobserver agreement for SSTR-RADS scoring among identical TL was good (intraclass correlation coefficient [ICC] for 4, 3, and 2 identical target lesions, ≥0.73, respectively). For lymph node and liver lesions, excellent interobserver agreement rates were derived (ICC, 0.91 and 0.77, respectively). Moreover, the interobserver agreement for an overall scan impression based on SSTR-RADS was excellent (ICC, 0.88). Decision for PRRT based on SSTR-RADS demonstrated an excellent agreement with an ICC of 0.8. No significant differences between ER and IR for overall scan impression and TL-based analyses were observed (p≥0.18, respectively), thereby suggesting that SSTR-RADS seems to be readily applicable even for less experienced readers. Conclusions: SSTR-RADS criteria demonstrated a high concordance rate, even among readers with different experience, supporting the adoption of SSTR-RADS for trials, or clinical routine. Further increase in interobserver reliability could be derived by stricter advice on selecting TL.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 61, Issue supplement 1
May 1, 2020
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High concordance rate on SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
High concordance rate on SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates
Rudolf Werner, Thorsten Derlin, Steven Rowe, Lena Bundschuh, Gabriel Sheikh, Martin Pomper, Andreas Buck, Frank Bengel, Ralph Bundschuh, Constantin Lapa
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 363;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
High concordance rate on SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates
Rudolf Werner, Thorsten Derlin, Steven Rowe, Lena Bundschuh, Gabriel Sheikh, Martin Pomper, Andreas Buck, Frank Bengel, Ralph Bundschuh, Constantin Lapa
Journal of Nuclear Medicine May 2020, 61 (supplement 1) 363;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis -> Clinical Therapy

  • First-in-human study of a novel SSTR antagonist177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with advanced metastatic NENs and low SSTR agonist binging
  • Mixed model time-activity fitting to reduce SPECT/CT imaging time points for dosimetry in Lu-177 peptide receptor radionuclide therapy (PRRT)
  • Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Show more Oncology: Clinical Therapy and Diagnosis -> Clinical Therapy

New Trends in Endocrine Therapy

  • Role of functional imaging for response assessment with Lu177-DOTATATE therapy for neuroendocrine tumors
  • Absorbed doses to kidneys based two SPECT measurements versus seven SPECT measurements patients with neuroendocrine tumours receiving 177Lu-DOTATATE therapy
  • Peptide Receptor Radionuclide Therapy as First Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumours
Show more New Trends in Endocrine Therapy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire